The antihistamine market is expected to gain a market value of USD 280 million by 2030 at a CAGR of 9.8% from 2022-2030.
Antihistamine is a drug that blocks histamine, an inflammatory chemical in the body. Histamine causes sneezing, runny nose, and watery eyes. It can treat allergies (such as hay fever), chronic obstructive pulmonary disease, asthma, and other diseases. It can also reduce the risk of strokes in patients with high blood pressure.
The major factors influencing the antihistamine drugs market are the growing prevalence of allergic reactions and allergies across the globe and increasing awareness in people about treating several allergic reactions. Furthermore, allergy treatments are expected to increase in demand due to the changing lifestyle and novel drug therapies. There is a large market for these treatments and an increase in population. However, the expiration of patented drugs and the introduction of generic versions of medications and side effects from treatment are expected to moderate the market growth during the forecast period. According to the American College of Allergy, Asthma and Immunology (ACAAI), allergic rhinitis (AR) has increased in the last three decades. In the US and Europe, more than 40% of the population is sensitive to inhalant allergens. The increased prevalence may be related to intensifying air pollution levels.
The COVID-19 pandemic positively impacted the sales of nasal antihistamines due to the most effective and popular mode of administration of nasal drugs. However, closed transnational borders, supply distribution channels, shortage of stock, and lockdown restrictions impacted sales of antihistamines to some extent.
According to forecasts from FMI, the COVID-19 market will recover in the next few years. This is accredited to the increasing demand for nasal sprays and more people relying on this treatment themselves. Amid transformations in healthcare, these trends are anticipated to continue, shaping the demand outlook positively.
The market is segmented on the basis of types which includes sedating and non-sedating antihistamines. Sedating antihistamines are further sub-segmented into brompheniramine, chlorpheniramine, diphenhydramine, doxylamine, carbinoxamine and others. Non-sedating antihistamines are further sub-segmented into fexofenadine, loratadine, loratadine odt, and others.
On the basis of route of administration, the antihistamine drugs market is segmented into oral route, parenteral route and rectal route. Parenteral route segmented is further sub-segmented into intramuscular, subcutaneous and intravenous route.
On the basis of indication, the market is segmented into allergy, urticaria, dermatitis, and others. And on the basis of end users, the market is segmented into hospitals, clinics, pharmaceutical companies and others.
The American region accounts for the largest share of the global market due to rising prevalence of allergy rhinitis and rising demand for diagnosis and treatment of allergic disease. According to the American College of Allergy Asthma and Immunology, allergic asthma, food allergy, and eczema are the most common types of allergies found in the U.S.
Europe is the second largest market that holds a noticeable share of the antihistamine drugs market. According to the European Academy of Allergy and Clinical Immunology (EAACI), more than 50% of all Europeans will suffer from allergy in coming years.
In Asia Pacific, increase in the demand for drugs for the treatment of allergies and skin diseases drive the antihistamine drugs market growth. There has been a rise in the number of dermatology clinics across Asia Pacific from past few years. High rates of allergic rhinitis and increasing awareness regarding treatments available for allergy is poised to drive the growth of market in Asia Pacific.
The Middle East & Africa, the market shows steady but positive growth due to the rising prevalence of nasal allergies.
Key Players in the Antihistamine drugs Market
Some of the key players in market are Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.)
Antihistamine drug manufacturers
Antihistamine drug suppliers
Medical research laboratories
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
|Market Size||238.65 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Route of Administration, Indication, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.)|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
The Antihistamine Drug Market valuation would be USD 238.65 Million 2030.
The CAGR would be 1090% during the forecast period of 2022 to 2030.
The players are Sanofi (France), Johnson & Johnson Consumer Inc. (U.S.), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), Bayer AG (Germany), and Prestige Brands Holdings, Inc. (U.S.).
The types are sedating and non-sedating antihistamines.
The types are allergy, urticaria, dermatitis, and others.